BRPI0409609A - mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia - Google Patents

mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia

Info

Publication number
BRPI0409609A
BRPI0409609A BRPI0409609-6A BRPI0409609A BRPI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A BR PI0409609 A BRPI0409609 A BR PI0409609A
Authority
BR
Brazil
Prior art keywords
treatment
hypercholesterolemia
cholesterol transport
reverse cholesterol
transport mediators
Prior art date
Application number
BRPI0409609-6A
Other languages
English (en)
Inventor
Jagadish C Sircar
Kashinatham Alisala
Igor Nikoulin
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BRPI0409609A publication Critical patent/BRPI0409609A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0819Tripeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MEDIADORES DO TRANSPORTE REVERSO DE COLESTEROL PARA O TRATAMENTO DA HIPERCOLESTEROLEMIA". A presente invenção proporciona composições adaptadas para estimular o transporte reverso de colesterol em mamíferos. As composições são adequadas para a transferência oral e úteis no tratamento e/ou prevenção da hipercolesterolemia, arteriosclerose e doenças cardiovasculares associadas.
BRPI0409609-6A 2003-04-22 2004-04-22 mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia BRPI0409609A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46466703P 2003-04-22 2003-04-22
PCT/US2004/012445 WO2004094471A2 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Publications (1)

Publication Number Publication Date
BRPI0409609A true BRPI0409609A (pt) 2006-04-18

Family

ID=33310929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409609-6A BRPI0409609A (pt) 2003-04-22 2004-04-22 mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia

Country Status (18)

Country Link
US (1) US20060166891A1 (pt)
EP (1) EP1615954A2 (pt)
JP (1) JP2007534612A (pt)
KR (1) KR20050114283A (pt)
CN (1) CN1809590A (pt)
AR (1) AR044058A1 (pt)
AU (1) AU2004233333A1 (pt)
BR (1) BRPI0409609A (pt)
CA (1) CA2522758A1 (pt)
CL (1) CL2004000858A1 (pt)
IS (1) IS8072A (pt)
MX (1) MXJL05000046A (pt)
NO (1) NO20055474L (pt)
PE (1) PE20050136A1 (pt)
RU (1) RU2005135139A (pt)
TW (1) TW200503747A (pt)
UY (1) UY28282A1 (pt)
WO (1) WO2004094471A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28953A1 (es) * 2004-06-09 2006-01-31 Avanir Pharmaceuticals Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
EP1753782A1 (en) * 2004-06-09 2007-02-21 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2005123700A1 (en) * 2004-06-09 2005-12-29 Avanir Pharmaceuticals Small molecules for treatment of hypercholesterolemia and related diseases
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
WO2009086096A2 (en) * 2007-12-21 2009-07-09 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
US20110288017A1 (en) * 2010-03-01 2011-11-24 Leslie Frost Apo-lipoprotein propeptide
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
AU2022300553B2 (en) * 2021-06-28 2025-06-19 Medi&Gene Inc. Peptide having antidiabetic activity and use thereof
CN113929737B (zh) * 2021-10-20 2024-07-23 中国科学院香港创新研究院再生医学与健康创新中心 一种多肽及其作为cck受体激动剂/拮抗剂的应用
WO2025024564A1 (en) * 2023-07-24 2025-01-30 The Board Of Regents Of The University Of Texas System Small molecules that prevent statin-induced accumulation of hmg coa reductase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE437153B (sv) * 1976-12-01 1985-02-11 Kabi Ab Specifika kromogena enzymsubstrat for serinproteaser
US4448715A (en) * 1981-11-02 1984-05-15 University Of Miami Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3781263T2 (de) * 1986-12-15 1993-04-08 Inst Nat Sante Rech Med Peptid-derivate und deren verwendung in der therapie.
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
IL158293A0 (en) * 2001-04-10 2004-05-12 Agensys Inc Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CN1809590A (zh) 2006-07-26
CL2004000858A1 (es) 2005-04-22
RU2005135139A (ru) 2007-05-27
MXJL05000046A (es) 2005-12-22
JP2007534612A (ja) 2007-11-29
WO2004094471A3 (en) 2005-06-16
UY28282A1 (es) 2004-11-30
US20060166891A1 (en) 2006-07-27
AU2004233333A1 (en) 2004-11-04
WO2004094471A2 (en) 2004-11-04
CA2522758A1 (en) 2004-11-04
NO20055474L (no) 2006-01-23
PE20050136A1 (es) 2005-04-20
KR20050114283A (ko) 2005-12-05
EP1615954A2 (en) 2006-01-18
AR044058A1 (es) 2005-08-24
IS8072A (is) 2005-10-13
TW200503747A (en) 2005-02-01
NO20055474D0 (no) 2005-11-18

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
SE0102315D0 (sv) Compounds
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004006858A3 (en) Compounds, compositions, and methods employing same
GEP20125565B (en) Lactam compounds and their pharmaceutical use
DE602004021644D1 (de) Gyraseinhibitoren und deren verwendungen
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
GB9902555D0 (en) Medicament
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
MXJL05000046A (es) Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
WO2005041881A3 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
TW200504051A (en) Novel acridine derivatives and their use as medicaments
GB0012795D0 (en) Organic compounds
BR0108096A (pt) Método para manter ou melhorar a sìntese de mucinas
BRPI0511945A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
BRPI0511871A (pt) moléculas pequenas para tratamento de hipercolesterolemia e doenças relacionadas
MXPA02003731A (es) Derivados novedosos de acido fusidico.
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
WO2005121160A3 (en) 11, 12 cyclic thiocarbamate macrolide antibacterial agents
FR2877572B1 (fr) Nouvelles compositions pharmaceutiques, alimentaires ou cosmetiques pour prevenir et traiter l'acne
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.